Register entry
GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 30
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
30| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 11643397 | JESDUVROQdaprodustat | substance | Jun 2027 |
| 8557834 | JESDUVROQdaprodustat | use | Jun 2027 |
| 8815884 | JESDUVROQdaprodustat | product | Jun 2027 |
| 8324208 | JESDUVROQdaprodustat | substance, product | Dec 2028 |
| 11117871 | JESDUVROQdaprodustat | substance, product | Mar 2038 |
| 11649217 | JESDUVROQdaprodustat | product | Mar 2038 |
| Product | Exclusivity | Until |
|---|---|---|
| JESDUVROQDAPRODUSTAT | NCE New chemical entity | Feb 2028 |
Enquiry
Common questions
- Is GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND FDA approved?
- GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.